DMHA shares similar structures to that of DMAA, DMBA (amp-citrate), and tuaminoheptane (2-aminoheptane), all of which are considered sympathomimetic stimulants or psychostimulants (drugs and/or supplements that promote wakefulness).
2-aminoisoheptane’s structural relations are known asmonoamine releasing agents, which are compounds that have the capability of increasing levels of certain monoamines. These monoamines, mostly, dopamine and norepinephrine, are responsible for exerting many of the common effects that stimulants produce – including nootropic like effects, euphoria, wakefullness (alertness), respectively.
In order for a compound to act as a releasing agent, the compounds must be structurally and metabolically related to the classical monoamine neurotransmitters. In the case of DMAA and its structural relatives like DMHA, they share this structure and are able to release both dopamine and norepinephrine through activation of trace amine associated receptor 1, while temporarily preventing their reuptake into the presynaptic nerve. This stops their ability to bind to target receptors, keeping dopamine and norepinephrine active longer, thereby producing the stimulant-like effect that we were previously used too, from hardcore pre-workouts of the past.